Abstract: Morbidity and mortality of the lung cancer increased very highly. Although recently chemotherapy， radiotherapy and molecular targeted therapy made great progress， five-year survival rate was not improved. Immune checkpoint inhibitors as the new direction for the treatment of tumors， have attracted attention due to the fact that they have the characteristics of efficiently and low toxicity. Current research on immune checkpoint inhibitors， such as CTLA-4， PD-1／PDL-1， Tim-3 and so on， have already been launched. In this review， we mainly summarized the progress in the immune checkpoint inhibitors in recent years.